TransCode Therapeutics’ (RNAZ) Buy Rating Reaffirmed at HC Wainwright

TransCode Therapeutics (NASDAQ:RNAZ)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Friday,Benzinga reports. They presently have a $3.00 price target on the stock.

TransCode Therapeutics Trading Down 4.0 %

NASDAQ:RNAZ opened at $0.35 on Friday. TransCode Therapeutics has a fifty-two week low of $0.22 and a fifty-two week high of $18.66. The stock has a fifty day moving average price of $0.49 and a 200-day moving average price of $0.69.

TransCode Therapeutics (NASDAQ:RNAZ) last posted its earnings results on Wednesday, August 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.16). Analysts expect that TransCode Therapeutics will post -2.06 earnings per share for the current year.

Institutional Trading of TransCode Therapeutics

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Virtu Financial LLC bought a new position in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 55,329 shares of the company’s stock, valued at approximately $37,000. Virtu Financial LLC owned approximately 0.84% of TransCode Therapeutics at the end of the most recent reporting period.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.